← Back to Clinical Trials
Recruiting NCT06116110
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Trial Parameters
Condition Non Hodgkin Lymphoma
Sponsor Miltenyi Biomedicine GmbH
Study Type OBSERVATIONAL
Phase N/A
Enrollment 150
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-05-15
Completion 2039-12-01
Interventions
Long-term Follow-Up
Brief Summary
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
Eligibility Criteria
Inclusion Criteria: * Received zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study and have either completed the study or have discontinued early from the study. * Provided written informed consent to participate in this study. Exclusion Criteria: * None
Related Trials
NCT06418204
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community
View Trial →
NCT05006716
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
View Trial →
NCT05605119
First in Human, Dose Escalation, Dose Expansion Study of AUR105
View Trial →